Barclays Initiates Coverage On Forte Biosciences with Overweight Rating, Announces Price Target of $74

Benzinga Newsdesk www.benzinga.com Positive 66.1%

Neg 0% Neu 0% Pos 66.1%

Barclays analyst Etzer Darout initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Overweight rating and announces Price Target of $74.